Researchers have identified early molecular warning signs of inflammatory bowel disease that suggest the condition can begin damaging gut tissue before symptoms appear and may continue silently even when patients seem well. The finding, from a WEHI-led study published in Science, points to a hidden defect in intestinal cells that could help explain why flare-ups return in people whose disease appears controlled.
A hidden defect that may precede flare-ups
The study found what the researchers described as a “smouldering” molecular defect in gut cells from people with inflammatory bowel disease. According to the report, the defect involved abnormal cell death and was detectable even in patients whose disease was well controlled.
The findings were produced in partnership with the Royal Melbourne Hospital and could help open new pathways for earlier prediction of flare-ups, more precise monitoring, and more tailored treatment. The research team said the damage appeared to be present in the earliest stages of disease activity, including in patients with clinically mild disease.
Why the discovery matters for patient care
Inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis, is a chronic condition that can cycle between periods of remission and sudden flare-ups that may require hospital care. The researchers said the new findings challenge the idea that cell death in IBD is simply a consequence of inflammation, and instead suggest it may be part of the process driving disease.
Study co-author Dr Andre Samson said the group found that even when patients seemed well, their intestinal cells were still primed for damage. Another co-author, Professor James Murphy, said the work revealed a molecular defect that shifts attention to the earliest stages of IBD. The researchers added that the results may not immediately lead to a new diagnostic test or treatment, but they provide a foundation for future prognostic tools and therapeutics.
What the study could mean next
The team said more sensitive molecular detection may eventually help clinicians keep patients in deep remission for longer and introduce new treatments aimed at reducing the frequency and severity of flares. The study also brought together scientists and clinicians from multiple institutions, including the University of Melbourne, the Royal Melbourne Hospital, Royal Children’s Hospital, Monash Institute of Pharmaceutical Sciences, the Hudson Institute of Medical Research and Monash University.
While the findings were reported in Australia, they are likely to attract interest in the UK and beyond, where researchers continue to look for better ways to predict disease activity and personalise treatment for patients living with chronic inflammatory conditions.
Photo source: AI-generated or edited image
